Neumora Therapeutics (NMRA) Total Current Liabilities (2022 - 2026)

Neumora Therapeutics has reported Total Current Liabilities for 5 years, with the latest figure at $30.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 6.1% year-over-year to $30.1 million; the trailing twelve-month figure through Mar 2026 stood at $30.1 million (up 6.1% YoY), and the FY2025 full-year result was $32.5 million, up 8.58% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $30.1 million, down from $32.5 million in the prior quarter.
• The five-year high for Total Current Liabilities was $32.5 million in Q4 2025, with the low at $21.2 million in Q2 2025.
• Average Total Current Liabilities over 5 years is $27.1 million, with a median of $27.1 million recorded in 2025.
• Year-over-year, Total Current Liabilities gained 19.02% in 2024 and decreased 18.59% in 2025.
• Tracing NMRA's Total Current Liabilities over 5 years: stood at $23.7 million in 2022, then gained by 5.97% to $25.1 million in 2023, then grew by 19.02% to $29.9 million in 2024, then grew by 8.58% to $32.5 million in 2025, then dropped by 7.2% to $30.1 million in 2026.
• The last three Total Current Liabilities figures came in at $30.1 million (Q1 2026), $32.5 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.

Peer Comparison